Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of high-dose ribavirin with epoetin beta support plus peginterferon alfa-2a in HIV/HCV coinfected prior nonresponders
2006-005554-74Phase 4Active
- Sponsor
- Fight AIDS and Infectious Diseases Foundation
- Start
- Feb 2007
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ribavirin, epoetin beta and peginterferon alfa-2a in hepatitis C virus infection, sponsored by Fight AIDS and Infectious Diseases Foundation. Primary endpoint: Early virologic response at week 12. Started Feb 2007; status: active.
02
Drugs
ribavirinepoetin betapeginterferon alfa-2a
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2006-005554-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005554-74.